Ensuring Patient-Centered Access to Cardiovascular Disease Medicines in Low-Income and Middle-Income Countries Through Health-System Strengthening

Cardiology Clinics

Volumn 35, Issue 1, 2017, Pages 125-134

  Tran, Dan N ^a   Njuguna, Benson ^a,b   Mercer, Timothy ^c   Manji, Imran ^a,b   Fischer, Lydia ^c   Lieberman, Marya ^d   Pastakia, Sonak D ^a  

^a PURDUE UNIVERSITY   (United States)

^b MOI TEACHING AND REFERRAL HOSPITAL   (Kenya)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF NOTRE DAME   (United States)

Author keywords

Accountability; Adherence; Availability; Cardiovascular disease medicines; Falsified and substandard medicines; Health system strengthening; Low income and middle income countries; Patient centered access

Indexed keywords

CARDIOVASCULAR AGENT;

CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; EVIDENCE BASED MEDICINE; FUNDING; HEALTH CARE ACCESS; HEALTH CARE AVAILABILITY; HEALTH INSURANCE; HUMAN; LOW INCOME COUNTRY; MIDDLE INCOME COUNTRY; PATIENT CARE; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SHORT MESSAGE SERVICE; SYSTEMATIC REVIEW (TOPIC); TEXT MESSAGING; WORLD HEALTH ORGANIZATION; CARDIOVASCULAR DISEASES; DEVELOPING COUNTRY; ECONOMICS; HEALTH CARE DELIVERY; ORGANIZATION AND MANAGEMENT; POVERTY; SOCIOECONOMICS; TRENDS;

CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; DEVELOPING COUNTRIES; HEALTH SERVICES ACCESSIBILITY; HUMANS; PATIENT-CENTERED CARE; POVERTY; SOCIOECONOMIC FACTORS;

EID: 84996805823     PISSN: 07338651     EISSN: 15582264     Source Type: Journal    
DOI: 10.1016/j.ccl.2016.08.008     Document Type: Review

References (69)

1. 1 GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 385:9963 (2015), 117–171.
2. 2 Mathers, C.D., Loncar, D., Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med, 3(11), 2006, e442.
3. 3 World Health Organization, Global status report on noncommunicable diseases 2014. 2014, World Health Organization, Geneva (Switzerland).
4. 4 Yusuf, S., Reddy, S., Ounpuu, S., et al. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation 104:22 (2001), 2746–2753.
5. 5 Fuster, V., Kelly, B.B., Vedanthan, R., Promoting global cardiovascular health: moving forward. Circulation 123:15 (2011), 1671–1678.
6. 6 Kishore, S.P., Kolappa, K., Jarvis, J.D., et al. Overcoming obstacles to enable access to medicines for noncommunicable diseases in poor countries. Health Aff (Millwood) 34:9 (2015), 1569–1577.
7. 7 Kishore, S.P., Vedanthan, R., Fuster, V., Promoting global cardiovascular health ensuring access to essential cardiovascular medicines in low- and middle-income countries. J Am Coll Cardiol 57:20 (2011), 1980–1987.
8. 8 Systems for Improved Access to Pharmaceuticals and Services (SIAPS), Enhancing health outcomes for chronic diseases in resource-limited settings by improving the use of medicines: the role of pharmaceutical care. Submitted to the U.S. Agency for International Development by the SIAPS Program. 2014, Management Sciences for Health, Arlington (VA).
9. 9 Cameron, A., Ewen, M., Ross-Degnan, D., et al. Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. Lancet 373:9659 (2009), 240–249.
10. 10 Mendis, S., Fukino, K., Cameron, A., et al. The availability and affordability of selected essential medicines for chronic diseases in six low- and middle-income countries. Bull World Health Organ 85:4 (2007), 279–288.
11. 11 Kankeu, H.T., Saksena, P., Xu, K., et al. The financial burden from non-communicable diseases in low- and middle-income countries: a literature review. Health Res Policy Syst, 11, 2013, 31.
12. 12 Almuzaini, T., Choonara, I., Sammons, H., Substandard and counterfeit medicines: a systematic review of the literature. BMJ Open, 3(8), 2013, e002923.
13. 13 Wirtz, V.J., Kaplan, W.A., Kwan, G.F., et al. Access to medications for cardiovascular diseases in low- and middle-income countries. Circulation 133:21 (2016), 2076–2085.
14. 14 Equitable access to essential medicines: a framework for collective action: WHO policy perspectives on medicines, No. 008, March 2004, 2004, World Health Organization, Geneva (Switzerland).
15. 15 van Mourik, M.S., Cameron, A., Ewen, M., et al. Availability, price and affordability of cardiovascular medicines: a comparison across 36 countries using WHO/HAI data. BMC Cardiovasc Disord, 10, 2010, 25.
16. 16 Khatib, R., McKee, M., Shannon, H., et al. Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data. Lancet 387:10013 (2016), 61–69.
17. 17 Yadav, P., Health product supply chains in developing countries: diagnosis of the root causes of underperformance and an agenda for reform. Health Systems & Reform 1:2 (2015), 142–154.
18. 18 Kaplan, W., Mathers, C., The world medicines situation 2011. 3rd edition, 2011, World Health Organization, Geneva (Switzerland).
19. 19 Lee, H.L., Padmanabhan, V., Whang, S., The bullwhip effect in supply chains. Sloan Manage Rev 38 (1997), 93–102.
20. 20 Sarley, D., Allain, L., Akkihal, A., et al. Estimating the global in-country supply chain costs of meeting the MDGs by 2015. 2009, USAID | DELIVER PROJECT, Arlington (VA) Task Order 1.
21. 21 Bateman, C., Drug stock-outs: inept supply-chain management and corruption. S Afr Med J 103:9 (2013), 600–602.
22. 22 Vian, T., Review of corruption in the health sector: theory, methods and interventions. Health Policy Plan 23:2 (2008), 83–94.
23. 23 Countering the problem of falsified and substandard drugs, 2013, Institute of Medicine of the National Academies, Washington, DC.
24. 24 Nayyar, G.M., Breman, J.G., Newton, P.N., et al. Poor-quality antimalarial drugs in southeast Asia and sub-Saharan Africa. Lancet Infect Dis 12:6 (2012), 488–496.
25. 25 Newton, P.N., Green, M.D., Fernandez, F.M., et al. Counterfeit anti-infective drugs. Lancet Infect Dis 6:9 (2006), 602–613.
26. 26 Antignac M, Diop BI, Macquart De Terline D, et al. Quality assessment of 7 cardiovascular drugs in SubSaharan African countries: results of the seven study by drug and version of drug World Congress of Cardiology and Cardiovascular Health. Mexico City, Mexico, June 4–7, 2016.
27. 27 Tumusiime P, Gonani A, Walker O, et al. Health systems in sub-Saharan Africa: what is their status and role in meeting the health Millennium Development Goals? African Health Monitor, Issue 14, March 2012.
28. 28 Campos, J.E., Pradhan, S., The many faces of corruption: tracking vulnerabilities at the sector level. 2007, World Bank, Washington, DC License: CC BY 3.0 IGO. Available at: https://openknowledge.worldbank.org/handle/10986/6848.
29. 29 Ho, P.M., Rumsfeld, J.S., Masoudi, F.A., et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med 166:17 (2006), 1836–1841.
30. 30 Fake medicines flood Kenyan market as experts warn of looming health crisis [press release]. Daily Nation; 2013.
31. 31 Anderson, C., Roy, T., FIP Global Pharmacy Workforce Report. 2012, International Pharmaceutical Federation (FIP), Netherlands.
32. 32 Chaudhury, N., Hammer, J., Kremer, M., et al. Missing in action: teacher and health worker absence in developing countries. J Econ Perspect 20:1 (2006), 91–116.
33. 33 Deussom, R., Jaskiewicz, W., Dwyer, S., et al. Absenteeism of health care providers in Machakos District, Kenya. 2008, Institute of Policy Analysis and Research (IPAR), Washington, DC IPAR Policy Brief 12, no. 2.
34. 34 Dowling, P., Healthcare supply chains in developing countries: situational analysis. 2011, USAID | DELIVER PROJECT, Arlington (VA) Task Order 4.
35. 35 Aday, L.A., Andersen, R., A framework for the study of access to medical care. Health Serv Res 9:3 (1974), 208–220.
36. 36 Frenk, J., White, K.L., The concept and measurement of accessibility. 1992, Pan American Health Organization, Washington, DC, 842–855.
37. 37 Andersen, R.M., Revisiting the behavioral model and access to medical care: does it matter?. J Health Soc Behav 36:1 (1995), 1–10.
38. 38 Gulliford, M., Figueroa-Munoz, J., Morgan, M., et al. What does ‘access to health care' mean?. J Health Serv Res Policy 7:3 (2002), 186–188.
39. 39 Mooney, G.H., Equity in health care: confronting the confusion. Eff Health Care 1:4 (1983), 179–185.
40. 40 Wald, N.J., Law, M.R., A strategy to reduce cardiovascular disease by more than 80%. BMJ, 326(7404), 2003, 1419.
41. 41 Mendis, S., Abegunde, D., Yusuf, S., et al. WHO study on prevention of REcurrences of Myocardial Infarction and StrokE (WHO-PREMISE). Bull World Health Organ 83:11 (2005), 820–829.
42. 42 Bloomfield, G.S., DeLong, A.K., Akwanalo, C.O., et al. Markers of atherosclerosis, clinical characteristics, and treatment patterns in heart failure: a case-control study of middle-aged adult heart failure patients in rural Kenya. Glob Heart 11:1 (2016), 97–107.
43. 43 Khatib, R., Schwalm, J.D., Yusuf, S., et al. Patient and healthcare provider barriers to hypertension awareness, treatment and follow up: a systematic review and meta-analysis of qualitative and quantitative studies. PLoS One, 9(1), 2014, e84238.
44. 44 Castellano, J.M., Copeland-Halperin, R., Fuster, V., Aiming at strategies for a complex problem of medical nonadherence. Glob Heart 8:3 (2013), 263–271.
45. 45 Pandey, K.R., Meltzer, D.O., Financial burden and impoverishment due to cardiovascular medications in low and middle income countries: an illustration from India. PLoS One, 11(5), 2016, e0155293.
46. 46 Ambaw, A.D., Alemie, G.A., W/Yohannes, S.M., et al. Adherence to antihypertensive treatment and associated factors among patients on follow up at University of Gondar Hospital, Northwest Ethiopia. BMC Public Health, 12, 2012, 282.
47. 47 Bhojani, U., Thriveni, B., Devadasan, R., et al. Out-of-pocket healthcare payments on chronic conditions impoverish urban poor in Bangalore, India. BMC Public Health, 12, 2012, 990.
48. 48 McIntyre, D., Thiede, M., Dahlgren, G., et al. What are the economic consequences for households of illness and of paying for health care in low- and middle-income country contexts?. Soc Sci Med 62:4 (2006), 858–865.
49. 49 Ho, P.M., Bryson, C.L., Rumsfeld, J.S., Medication adherence: its importance in cardiovascular outcomes. Circulation 119:23 (2009), 3028–3035.
50. 50 Garner, P., The Bamako initiative. BMJ 299:6694 (1989), 277–278.
51. 51 Murakami, H., Phommasack, B., Oula, R., et al. Revolving drug funds at front-line health facilities in Vientiane, Lao PDR. Health Policy Plan 16:1 (2001), 98–106.
52. 52 Uzochukwu, B.S., Onwujekwe, O.E., Akpala, C.O., Effect of the Bamako-Initiative drug revolving fund on availability and rational use of essential drugs in primary health care facilities in south-east Nigeria. Health Policy Plan 17:4 (2002), 378–383.
53. 53 Manji, I., Manyara, S.M., Jakait, B., et al. The Revolving Fund Pharmacy Model: backing up the Ministry of Health supply chain in western Kenya. Int J Pharm Pract 24 (2016), 358–366.
54. 54 Barrington, J., Wereko-Brobby, O., Ward, P., et al. SMS for Life: a pilot project to improve anti-malarial drug supply management in rural Tanzania using standard technology. Malar J, 9, 2010, 298.
55. 55 Kovacs, S., Hawes, S.E., Maley, S.N., et al. Technologies for detecting falsified and substandard drugs in low and middle-income countries. PLoS One, 9(3), 2014, e90601.
56. 56 Paper Analytical Device Project. Available at: http://padproject.nd.edu/. Accessed June 5, 2016.
57. 57 Joshi, R., Alim, M., Kengne, A.P., et al. Task shifting for non-communicable disease management in low and middle income countries—a systematic review. PLoS One, 9(8), 2014, e103754.
58. 58 Task shifting: rational redistribution of tasks among health workforce teams, 2008, World Health Organization, Geneva (Switzerland).
59. 59 Ogedegbe, G., Gyamfi, J., Plange-Rhule, J., et al. Task shifting interventions for cardiovascular risk reduction in low-income and middle-income countries: a systematic review of randomised controlled trials. BMJ Open, 4(10), 2014, e005983.
60. 60 Adeyemo, A., Tayo, B.O., Luke, A., et al. The Nigerian antihypertensive adherence trial: a community-based randomized trial. J Hypertens 31:1 (2013), 201–207.
61. 61 Mendis, S., Johnston, S.C., Fan, W., et al. Cardiovascular risk management and its impact on hypertension control in primary care in low-resource settings: a cluster-randomized trial. Bull World Health Organ 88:6 (2010), 412–419.
62. 62 Nesari, M., Zakerimoghadam, M., Rajab, A., et al. Effect of telephone follow-up on adherence to a diabetes therapeutic regimen. Jpn J Nurs Sci 7:2 (2010), 121–128.
63. 63 Xavier, D., Gupta, R., Kamath, D., et al. Community health worker-based intervention for adherence to drugs and lifestyle change after acute coronary syndrome: a multicentre, open, randomised controlled trial. Lancet Diabetes Endocrinol 4:3 (2016), 244–253.
64. 64 Vedanthan, R., Kamano, J.H., Naanyu, V., et al. Optimizing linkage and retention to hypertension care in rural Kenya (LARK hypertension study): study protocol for a randomized controlled trial. Trials, 15, 2014, 143.
65. 65 Ford, N., Nachega, J.B., Engel, M.E., et al. Directly observed antiretroviral therapy: a systematic review and meta-analysis of randomised clinical trials. Lancet 374:9707 (2009), 2064–2071.
66. 66 Shaffer, J., Wexler, L.F., Reducing low-density lipoprotein cholesterol levels in an ambulatory care system. Results of a multidisciplinary collaborative practice lipid clinic compared with traditional physician-based care. Arch Intern Med 155:21 (1995), 2330–2335.
67. 67 Lonn, E., Bosch, J., Teo, K.K., et al. The polypill in the prevention of cardiovascular diseases: key concepts, current status, challenges, and future directions. Circulation 122:20 (2010), 2078–2088.
68. 68 Yusuf, S., Lonn, E., Pais, P., et al. Blood-pressure and cholesterol lowering in persons without cardiovascular disease. N Engl J Med 374:21 (2016), 2032–2043.
69. 69 Beran, D., McCabe, A., Yudkin, J.S., Access to medicines versus access to treatment: the case of type 1 diabetes. Bull World Health Organ 86:8 (2008), 648–649.